Current progression of bevacizumab in advanced non-small cell lung cancer
10.3760/cma.j.issn.0253-3766.2018.10.013
- VernacularTitle: 贝伐珠单抗治疗晚期非小细胞肺癌的研究进展
- Author:
Tianqing CHU
1
;
Jihua CHEN
2
;
Baohui HAN
1
Author Information
1. Department of Respiratory Disease, Chest Hospital of Shanghai Jiaotong University, Shanghai 200030, China
2. Medical Department of China, Shanghai Roche Pharmaceuticals Ltd., Shanghai 201203, China
- Publication Type:Journal Article
- Keywords:
Carcinoma, non-small-cell lung;
Bevacizumab;
Epidermal growth factor receptor;
Prognosis
- From:
Chinese Journal of Oncology
2018;40(10):793-800
- CountryChina
- Language:Chinese
-
Abstract:
Non-small cell lung cancer (NSCLC) is one of the malignant diseases with high morbidity, high mortality and poor prognosis in China and worldwide, and the progression of which is significantly related to abnormal angiogenesis. Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), inhibits angiogenesis during tumor progression. It has been widely demonstrated to improve the survival of NSCLC patients. Therefore, bevacizumab is approved and recommended as the first-line treatment of advanced NSCLC by a number of countries and regions. In this paper, various large-scale clinical trials are analyzed to highlight the current clinical applications of bevacizumab in advanced NSCLC, especially patients with EGFR mutations. In addition, this review focuses on the efficacy, safety and predict factors of bevacizumab as anti-angiogenic therapy, in order to screen the patients who can acquire the maximal benefit.
